Clinical trials: Castration-Resistant Prostate Cancer
Prostate Cancer, Castration-resistant Prostate Cancer
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.
- Trial name
- NCT03741712
- Testing
- SHR3680, SHR2554
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration resistant prostate cancer (m-CRPC)…
- Trial name
- NCT04060394
- Testing
- Phase I and Phase II: LAE001/prednisone + afuresertib
- Where
- 17 sites in United States, South Korea
- Volunteers
- 49 people
- Sponsor
- Laekna Limited
Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.
- Trial name
- NCT06241846
- Testing
- YL201 for Injection
- Where
- 24 sites in China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Castration Resistant Prostate Cancer (mCRPC)
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other…
- Trial name
- EPIX (NCT04516161)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- United States
- Volunteers
- 1,180 people
- Sponsor
- Bayer
Castration-Resistant Prostatic Cancer, Metastasis
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT06863272
- Testing
- Docetaxel, Ifinatamab Deruxtecan, Opevesostat
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 360 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Castration-Resistant Prostate Cancer (CRPC)
Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer
The purpose of this clinical study is to evaluate the safety, tolerability, and efficacy of CP-PCA07 in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT07683013
- Testing
- CP-PCA07, Enzalutamide 40 mg capsule
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Hyundai Bioscience Co., Ltd.
Prostate Cancer
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care
The purpose of this registry is to document the characteristics and management of patients with metastatic castrate resistant prostate cancer (mCRPC) in routine clinical practice, independent of treatment used.
- Trial name
- NCT02236637
- Where
- 146 sites in Austria, Belgium and 13 more
- Volunteers
- 3,050 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Castration-Resistant Prostatic Cancer, Metastatic Disease
Safety and Targeting of Anti-hk2 Antibody in mCRPC
This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This imaging study will be conducted to confirm the safety and estimate the mass amount of antibody h11B6, and confirm in vivo…
- Trial name
- NCT04116164
- Testing
- 111In-DOTA-h11B6
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- SpectronRX
Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
This is a Phase 1b/Phase 2a, open-label, multicenter study to determine the safety, tolerability, recommended Phase 2 dose (RP2D), efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) properties of idronoxil when rectally…
- Trial name
- NCT04957290
- Testing
- NOX66, EBRT
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Noxopharm Limited
Prostate Cancer
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).
- Trial name
- ARMOR1 (NCT00959959)
- Testing
- TOK-001
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- LTN PHARMACEUTICALS, INC.
Prostatic Neoplasms
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate pharmacokinetics (PK) following a single dose and multiple dose treatment and the safety of apalutamide in Chinese participants with metastatic castration resistant prostate cancer (mCRPC)…
- Trial name
- NCT03523442
- Testing
- Apalutamide
- Where
- 4 sites in China
- Volunteers
- 19 people
- Sponsor
- Janssen Research & Development, LLC
Hormone Refractory Prostate Cancer
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of…
- Trial name
- NCT00571675
- Testing
- AT-101, prednisone and docetaxel
- Where
- 35 sites in United States, Russia
- Volunteers
- 220 people
- Sponsor
- Ascenta Therapeutics
Prostate Cancer
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipataseritib administrated in combination with abiraterone and of…
- Trial name
- NCT01485861
- Testing
- Abiraterone, Apitolisib, Ipatasertib
- Where
- 59 sites in United States, Czechia and 7 more
- Volunteers
- 298 people
- Sponsor
- Genentech, Inc.
Metastatic Prostate Cancer
Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
This non-interventional, observational, multicenter, prospective cohort study is designed to investigate the treatment patterns of mPC patients treated with lutetium (177Lu) vipivotide tetraxetan, as well as their clinical…
- Trial name
- PSMAreal (NCT07290270)
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Neoplasms
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine the effect of abiraterone acetate plus prednisone on the conduction of electric charges within the heart and to determine the blood levels of abiraterone acetate following administration…
- Trial name
- NCT00910754
- Testing
- Abiraterone acetate, Prednisone
- Where
- 8 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
This is a prospective, open-label, dose-escalation and randomized dose optimization and expansion study. The Phase Ib portion of the study aims to determine the safety and tolerability of escalating doses of [212Pb]Pb-ADVC001…
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
- Trial name
- NCT05720130
- Testing
- [²¹²Pb]Pb-ADVC001 (Phase 1b), [²¹²Pb]Pb-ADVC001 (Phase 2a)
- Where
- 3 sites in Australia
- Volunteers
- 100 people
- Sponsor
- AdvanCell Pty Limited
Metastatic Castration Resistant Prostate Cancer
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
This was an open-label, multicenter, prospective trial to assess safety and efficacy of 177Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer.
- Trial name
- RESIST-PC (NCT03042312)
- Testing
- 177Lu-PSMA-617
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Endocyte
Prostate Cancer
Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer
20 patients with invasive castration resistant prostate cancer and radiologically verified metastases will be enrolled into the Phase I Clinical Trial. The trial is a dendritic cell based immunotherapy.
- Trial name
- CryoIT (NCT02423928)
- Testing
- Dendritic cell based cryoimmunotherapy, Cyclophosphamide, ipilimumab
- Where
- Norway
- Volunteers
- 18 people
- Sponsor
- Alden Cancer Therapy II
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.